Broderick Brian C Reduces Holdings in Danaher Corporation $DHR

Broderick Brian C lowered its position in shares of Danaher Corporation (NYSE:DHR) by 4.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 63,349 shares of the conglomerate’s stock after selling 2,947 shares during the period. Danaher comprises about 2.5% of Broderick Brian C’s holdings, making the stock its 19th largest position. Broderick Brian C’s holdings in Danaher were worth $12,514,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. MGO One Seven LLC raised its position in Danaher by 485.7% in the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock valued at $5,145,000 after purchasing an additional 20,813 shares during the last quarter. Chicago Capital LLC increased its stake in Danaher by 11.6% in the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock valued at $2,634,000 after purchasing an additional 1,391 shares during the period. UniSuper Management Pty Ltd raised its holdings in shares of Danaher by 1.6% in the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock valued at $34,954,000 after buying an additional 2,667 shares during the last quarter. Asahi Life Asset Management CO. LTD. purchased a new stake in shares of Danaher in the first quarter valued at about $539,000. Finally, Horizon Financial Services LLC boosted its stake in shares of Danaher by 20,400.0% during the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate’s stock worth $1,681,000 after buying an additional 8,160 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Performance

NYSE:DHR opened at $208.63 on Wednesday. The firm’s fifty day simple moving average is $200.40 and its 200-day simple moving average is $197.32. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock has a market cap of $149.39 billion, a PE ratio of 44.39, a price-to-earnings-growth ratio of 3.02 and a beta of 0.77. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.41.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter in the previous year, the firm earned $1.72 earnings per share. The firm’s revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s payout ratio is currently 27.23%.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 11.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

DHR has been the topic of several recent research reports. Evercore ISI boosted their price target on Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research report on Tuesday. Guggenheim reiterated a “buy” rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 target price on Danaher in a report on Tuesday, September 2nd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Danaher in a report on Saturday, September 27th. Finally, Barclays reissued an “overweight” rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $245.63.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.